AIM ImmunoTech Enters Manufacturing Agreement for Ampligen Precursors

What Happened AIM ImmunoTech (AIM) announced on July 31, 2026 that it entered a Proposal Agreement with Sterling Pharma Solutions to manufacture additional batches of the polynucleotide drug substances PolyI and Poly C12U and transfer associated test methods at Sterling’s Dudley, UK site. The work is tied to prior Master Service and Quality Agreements from 2022. The estimated cost to AIM under the Proposal Agreement is approximately $1.5 million, to be paid over 12 months. AIM expects to use the manufactured material for ongoing and future clinical trials, potentially including a Phase 3 trial in metastatic pancreatic cancer. The full Proposal Agreement is attached as Exhibit 10.1 to the 8-K.

Key Details

• Agreement date: July 31, 2026; counterparty: Sterling Pharma Solutions (manufacturer).
• Scope: Manufacture of PolyI and Poly C12U and transfer of test methods at Dudley, UK to produce polymer precursors for Ampligen.
• Estimated cost: ~$1.5 million, payable over ~12 months.
• Corporate governance note: Stockholder director nomination notice window for the 2026 annual meeting is Aug 18–Sept 17, 2026 (5:00 p.m. local time); universal-proxy Rule 14a-19 notices due by Oct 19, 2026.

Why It Matters This agreement secures a near-term supply and analytic transfer for key precursors used to make Ampligen, which can reduce manufacturing risk and support AIM’s clinical development plans. The cash commitment is relatively modest (~$1.5M) but directly tied to advancing material availability for potential late-stage trials. The filing also reminds investors of upcoming deadlines for shareholder director nominations, relevant for anyone considering proxy contests or alternate nominees.